RegeneRx Biopharmaceuticals, Inc. Plans Test of TB4 Eye Drops to Reduce Chemical Eye Damage

June 25, 2009

RegeneRx Biopharmaceuticals, Inc. has announced testing of TB4 in a joint project with U.S. Army Medical Research Institute of Chemical Defense and researchers with Wayne State University. The researchers will evaluate the eye drops’ ability to prevent or reduce damage to the eye from exposure to chemical agents. ┬áBoth the military and homeland security are very interested in preventing such damage. The project will consist of a series of experiments over the next 12 months using TB4.

Dr. Gabriel Sosne and colleagues from Wayne State University have published several studies that evaluate TB4’s ability to reduce damage by a number of chemical agents. Other researchers also have noted TB4’s ability to promote stem cell differentiation in skin and heart tissue.

TB4 is currently in phase II clinical trials.

Read the release.




Jump down to form below to submit your own comments

Comments are closed.